Cephalon rejects Valeant unsolicited acquisition offer for $5.7B

Cephalon Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Valeant Pharmaceuticals International Inc.

Canada / Mid-Cap Biopharma ($1-$50 billion)

$13,665.5m on 03/25/2011 [market cap]

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Canceled

Sample

01/01/2009

announced

01/01/2009

Canceled